Sohini Das

India's pharmaceutical industry remains dependent on China for bulk drugs, particularly fermentation-based antibiotics, vitamins and intermediates

Replacement demand recovery is expected to support near-term growth, while rising electrification and changing consumer preferences may drive scooters to overtake motorcycles in the long run

Ather plans to reduce aluminium content in scooters to cut costs and improve margins, with up to 15 per cent savings expected on its upcoming EL platform

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Orbicular Pharma and Apotex secure tentative US FDA approval for generic Ozempic, marking entry into fast-growing semaglutide market pending patent clearance

Automaker aims to double India market share with new models, alternate fuel push and potential entry into sub-4 metre SUV segment by 2030

Strong demand for top-end luxury cars and EVs helps the carmaker post 5% sequential growth despite volatility, currency pressure and rising import costs

Indian pharma market's growth was led more by price increases that an uptick in consumption

VinFast and BYD outpace the US EV giant with sharper pricing, faster localisation signals and wider networks, even as Tesla sticks to an import-led strategy

Kiran Mazumdar-Shaw urges IPO reforms, saying India's listing norms hinder biotech firms that need long R&D cycles before generating revenue

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Co says strong product mix, multi-powertrain strategy drive volume and market share gains

High base effect, weak pentup demand, and West Asia conflict to temper momentum

US tariffs on patented drugs may have limited immediate impact on India, but industry flags uncertainty as policy ties relief to pricing and manufacturing shifts

Report flags global patent cliff and rising R&D costs as catalysts, with India emerging as a cost-efficient hub backed by policy support, faster trials and expanding biotech ecosystem

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

A global study finds India's young adults scoring far below older generations on mental health, with rising consumption of ultra-processed food and increasing screen exposure emerging as key risks

Hybrids emerge as the preferred bridge technology as most buyers stay price-conscious, favour lower EMIs and take a cautious view on full electrification

Pune-based Sedemac is engaging global OEMs to export its proprietary ISG technology, even as TVS, Bajaj and Hero scale domestic deployment ahead of the firm's March 2026 IPO

India-Brazil pharma meet highlights Brazil's growing role as a priority market for Indian MSME drugmakers, driven by rising exports, regulatory engagement and demand for specialty medicines